<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04904549</url>
  </required_header>
  <id_info>
    <org_study_id>VAT00008</org_study_id>
    <secondary_id>U1111-1264-3238</secondary_id>
    <nct_id>NCT04904549</nct_id>
  </id_info>
  <brief_title>Study of Monovalent and Bivalent Recombinant Protein Vaccines Against COVID-19 in Adults 18 Years of Age and Older</brief_title>
  <acronym>VAT00008</acronym>
  <official_title>A Parallel-group, Phase III, Multi-stage, Modified Double-blind, Multi-armed Study to Assess the Efficacy, Safety, and Immunogenicity of Two SARS-CoV-2 Adjuvanted Recombinant Protein Vaccines (Monovalent and Bivalent) for Prevention Against COVID-19 in Adults 18 Years of Age and Older</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of the study are:&#xD;
&#xD;
        -  To assess, in participants who are severe acute respiratory syndrome coronavirus 2&#xD;
           (SARS-CoV-2) naïve, the clinical efficacy of the SARS-CoV-2 vaccines for the prevention&#xD;
           of symptomatic COVID-19 occurring ≥ 14 days after the second injection.&#xD;
&#xD;
        -  To assess the safety of the SARS-CoV-2 vaccines compared to placebo throughout the&#xD;
           study.&#xD;
&#xD;
      The main secondary objectives of the study are to assess, in SARS-CoV-2 naïve participants,&#xD;
      the efficacy of the SARS-CoV-2 vaccines against:&#xD;
&#xD;
        -  SARS-CoV-2 infection occurring ≥ 14 days after the second injection.&#xD;
&#xD;
        -  Severe disease occurring ≥ 14 days after the second injection.&#xD;
&#xD;
        -  Asymptomatic infection and symptomatic COVID-19 occurring ≥ 14 days after the first&#xD;
           injection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The duration of participation in the study will be approximately 365 days post-last injection&#xD;
      (ie, approximately 386 days total) for each participant.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 26, 2021</start_date>
  <completion_date type="Anticipated">January 27, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 27, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The study is designed to demonstrate clinical efficacy of each of the two SARS-CoV-2 adjuvanted recombinant protein vaccines (monovalent and bivalent). In Stage 1, the monovalent vaccine will be evaluated against a placebo control. In Stage 2, bivalent vaccine will be assessed against a placebo control.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Participants, outcome assessors, Investigators, laboratory personnel, and sponsor trial staff are blinded to intervention group; and those preparing the study interventions are unblinded to vaccine assignment group.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrences of symptomatic COVID-19</measure>
    <time_frame>From ≥ 14 days after the second injection to Day 387</time_frame>
    <description>Symptomatic COVID-19 is defined as virologically-confirmed SARS-CoV-2 infection accompanied by protocol-defined COVID-19-like illness.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Presence of solicited injection site or systemic reactions</measure>
    <time_frame>Within 7 days after vaccination</time_frame>
    <description>Injection site reactions: injection site pain, erythema and swelling. Systemic reactions: fever, headache, malaise, myalgia, arthralgia and chills.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Presence of non-serious unsolicited adverse events</measure>
    <time_frame>Within 21 days after vaccination</time_frame>
    <description>Adverse events other than solicited reactions.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Presence of immediate adverse events</measure>
    <time_frame>Within 30 minutes after vaccination</time_frame>
    <description>Immediate adverse events include unsolicited injection site and systemic adverse events occurring within 30 minutes after injection.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Presence of medically attended adverse events</measure>
    <time_frame>From Day 1 to Day 387</time_frame>
    <description>Medically attended adverse events will be assessed throughout the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Presence of serious adverse events</measure>
    <time_frame>From Day 1 to Day 387</time_frame>
    <description>Serious adverse events will be assessed throughout the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Presence of adverse events of special interest</measure>
    <time_frame>From Day 1 to Day 387</time_frame>
    <description>Adverse events of special interest will be assessed throughout the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Presence of virologically-confirmed SARS-CoV-2 infections and/or symptomatic COVID-19</measure>
    <time_frame>From Day 1 to Day 387</time_frame>
    <description>Percentage of participants with positive result for SARS-CoV-2 infection by Nucleic Acid Amplification Test (NAAT) on at least one respiratory sample accompanied or not by protocol-defined clinical COVID-19 symptoms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrences of SARS-CoV-2 infection</measure>
    <time_frame>From ≥ 14 days after the second injection to Day 387</time_frame>
    <description>SARS-CoV-2 infection is defined as a serologically-confirmed SARS-CoV-2 infection or virologically-confirmed SARS-CoV-2 infection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of severe COVID-19</measure>
    <time_frame>From ≥ 14 days after the second injection to Day 387</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrences of asymptomatic SARS-CoV-2 infection</measure>
    <time_frame>From Day 1 to Day 387</time_frame>
    <description>Asymptomatic SARS-CoV-2 infection is defined as SARS-CoV-2 infection, with no reported COVID-19-like illness episodes between enrollment and 14 days after the timepoint at which SARS-CoV-2 infection is ascertained.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral copies/mL in respiratory samples</measure>
    <time_frame>From Day 1 to Day 387</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days with positive NAAT</measure>
    <time_frame>From Day 1 to Day 387</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrences of positive NAAT in respiratory samples at each follow-up timepoint during symptomatic COVID-19</measure>
    <time_frame>From Day 1 to Day 387</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrences of Centers for Disease Control and Prevention (CDC)-defined COVID-19</measure>
    <time_frame>From Day 1 to Day 387</time_frame>
    <description>Virologically-confirmed SARS-CoV-2 infection with at least one of CDC-defined clinical symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrences of hospitalized COVID-19</measure>
    <time_frame>From Day 1 to Day 387</time_frame>
    <description>Hospitalized COVID-19 is defined as an episode of symptomatic COVID-19 that requires inpatient hospitalization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrences of symptomatic COVID-19 with severity of moderate COVID-19 or worse.</measure>
    <time_frame>From Day 1 to Day 387</time_frame>
    <description>Composite endpoint of at least one of moderate or severe COVID-19.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutralizing antibody titer</measure>
    <time_frame>Day 1, Day 22, Day 43, Day 78, Day 134, Day 202, Day 292, and Day 387</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responders, as determined by neutralizing antibody titers</measure>
    <time_frame>Day 1, Day 22, Day 43, Day 78, Day 134, Day 202, Day 292, and Day 387</time_frame>
    <description>Responders are defined as participants who had baseline values below lower limit of quantification (LLOQ) with quantifiable neutralization titer above assay LLOQ at each pre-defined post-vaccination time point and participants with baseline values above LLOQ with a 4-fold increase in neutralizing antibody</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutralizing antibody titer fold-rise post-vaccination at all pre-defined time points</measure>
    <time_frame>Day 1, Day 22, Day 43, Day 78, Day 134, Day 202, Day 292, and Day 387</time_frame>
    <description>Fold-rise in antibody neutralization titer post-vaccination relative to Day 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2-fold rise and 4-fold-rise in neutralization antibody titer at all pre-defined time points</measure>
    <time_frame>Day 1, Day 22, Day 43, Day 78, Day 134, Day 202, Day 292, and Day 387</time_frame>
    <description>Fold-rise in antibody neutralization titer post-vaccination relative to Day 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of symptoms associated with symptomatic COVID-19 episode</measure>
    <time_frame>From Day 1 to Day 387</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrences of COVID-19 in each severity rating</measure>
    <time_frame>From Day 1 to Day 387</time_frame>
    <description>COVID-19 severity score based on the ordinal scale of clinical assessment (7-point ordinal scale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death associated with COVID-19</measure>
    <time_frame>From Day 1 to day 387</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">21046</enrollment>
  <condition>COVID-19 (Healthy Volunteers)</condition>
  <arm_group>
    <arm_group_label>Stage 1: SARS-CoV-2 vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 injections of monovalent SARS-CoV-2 vaccine at Day 1 and Day 22</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 1: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 injections of placebo at Day 1 and Day 22</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 2: SARS-CoV-2 vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 injections of bivalent SARS-CoV-2 vaccine at Day 1 and Day 22</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 2: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 injections of placebo at Day 1 and Day 22</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SARS-CoV-2 adjuvanted recombinant protein vaccine (monovalent)</intervention_name>
    <description>Pharmaceutical form: emulsion for injection. Route of administration: intramuscular injection</description>
    <arm_group_label>Stage 1: SARS-CoV-2 vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SARS-CoV-2 adjuvanted recombinant protein vaccine (bivalent)</intervention_name>
    <description>Pharmaceutical form: emulsion for injection. Route of administration: intramuscular injection.</description>
    <arm_group_label>Stage 2: SARS-CoV-2 vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Pharmaceutical form: liquid. Route of administration: intramuscular administration.</description>
    <arm_group_label>Stage 1: Placebo</arm_group_label>
    <arm_group_label>Stage 2: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged 18 years or older on the day of inclusion.&#xD;
&#xD;
          -  For persons living with human immunodeficiency virus (HIV), stable HIV infection&#xD;
             determined by participant currently on antiretrovirals with CD4 count &gt; 200/mm3.&#xD;
&#xD;
          -  SARS-CoV-2 rapid serodiagnostic test performed at the time of enrollment to detect&#xD;
             presence of SARS-CoV-2 antibodies.&#xD;
&#xD;
          -  Does not intend to receive an authorized/approved COVID-19 vaccine despite&#xD;
             encouragement by the Investigator to receive the authorized vaccine available to them&#xD;
             at the time of enrollment.&#xD;
&#xD;
          -  A female participant is eligible to participate if she is not pregnant or&#xD;
             breastfeeding and one of the following conditions applies:&#xD;
&#xD;
          -  Is of non-childbearing potential. To be considered of non-childbearing potential, a&#xD;
             female must be post-menopausal for at least 1 year or surgically sterile, or&#xD;
&#xD;
          -  Is of childbearing potential and agrees to use an effective contraceptive method or&#xD;
             abstinence from at least 4 weeks prior to the first study intervention administration&#xD;
             until at least 12 weeks after the second study intervention administration.&#xD;
&#xD;
        A participant of childbearing potential must have a negative highly sensitive pregnancy&#xD;
        test (urine or serum as required by local regulation).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Participants are excluded from the study if any of the following criteria apply:&#xD;
&#xD;
          -  Known systemic hypersensitivity to any of the vaccine components, or history of a&#xD;
             life-threatening reaction to a vaccine containing any of the same substances.&#xD;
&#xD;
          -  Dementia or any other cognitive condition at a stage that could interfere with&#xD;
             following the study procedures based on Investigator's judgment.&#xD;
&#xD;
          -  Self-reported thrombocytopenia, contraindicating intramuscular (IM) vaccination based&#xD;
             on Investigator's judgment&#xD;
&#xD;
          -  Bleeding disorder, or receipt of anticoagulants in the past 21 days preceding&#xD;
             inclusion, contraindicating IM vaccination based on Investigator's judgment.&#xD;
&#xD;
          -  Unstable acute or chronic illness that in the opinion of the Investigator or designee&#xD;
             poses additional risk as a result of participation or that could interfere with the&#xD;
             study procedures.&#xD;
&#xD;
          -  Moderate or severe acute illness/infection (according to investigator judgment) on the&#xD;
             day of vaccination or febrile illness (temperature ≥ 38.0°C [≥ 100.4°F]). A&#xD;
             prospective participant should not be included in the study until the condition has&#xD;
             resolved or the febrile event has subsided.&#xD;
&#xD;
          -  Receipt of any vaccine in the 30 days preceding or on the day of the first study&#xD;
             vaccination or planned receipt of any vaccine between the first study vaccination and&#xD;
             in the 30 days following the second study vaccination except for influenza&#xD;
             vaccination, which may be received at any time in relation to study intervention.&#xD;
&#xD;
          -  Prior administration of a coronavirus vaccine (SARS-CoV-2, SARS-CoV, Middle East&#xD;
             Respiratory Syndrome).&#xD;
&#xD;
          -  Receipt of solid-organ or bone marrow transplants in the past 180 days.&#xD;
&#xD;
          -  Receipt of anti-cancer chemotherapy in the last 90 days.&#xD;
&#xD;
          -  Participation at the time of study enrollment (or in the 30 days preceding the first&#xD;
             study vaccination) or planned participation during the present study period in another&#xD;
             clinical study investigating a vaccine, drug, medical device, or medical procedure.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Trial Transparency email recommended (Toll free number for US &amp; Canada)</last_name>
    <phone>800-633-1610</phone>
    <phone_ext>option 6</phone_ext>
    <email>Contact-US@sanofi.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Investigational Site Number :8400004</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400019</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35802</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400021</name>
      <address>
        <city>Rolling Hills Estates</city>
        <state>California</state>
        <zip>90274</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400013</name>
      <address>
        <city>Centennial</city>
        <state>Colorado</state>
        <zip>80112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400002</name>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <zip>32934</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400020</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400017</name>
      <address>
        <city>Pinellas Park</city>
        <state>Florida</state>
        <zip>33781</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400005</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400024</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400012</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60602</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400026</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400008</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47714</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400006</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400018</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89052</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400023</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400009</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44311</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400010</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45236</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400011</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400007</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400022</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400025</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400003</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400014</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400015</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :8400016</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :1700002</name>
      <address>
        <city>Barranquilla</city>
        <zip>080020</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :1700001</name>
      <address>
        <city>Bogota</city>
        <zip>111611</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :1700005</name>
      <address>
        <city>Cali</city>
        <zip>760002</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :1700006</name>
      <address>
        <city>Chia</city>
        <zip>0000</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :1700004</name>
      <address>
        <city>Floridablanca</city>
        <zip>681004</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :1700007</name>
      <address>
        <city>Girardot</city>
        <zip>00000</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :1700003</name>
      <address>
        <city>Soledad</city>
        <zip>083001</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :2880002</name>
      <address>
        <city>Kintampo</city>
        <zip>P. O. Box 200</zip>
        <country>Ghana</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :2880003</name>
      <address>
        <city>Kumasi</city>
        <zip>00000</zip>
        <country>Ghana</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :2880001</name>
      <address>
        <city>Navrongo</city>
        <zip>114</zip>
        <country>Ghana</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 2880001</name>
      <address>
        <city>Navrongo</city>
        <country>Ghana</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :3400001</name>
      <address>
        <city>Municipio Del Distrito Central</city>
        <zip>11101</zip>
        <country>Honduras</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :3400002</name>
      <address>
        <city>San Pedro Sula</city>
        <zip>21104</zip>
        <country>Honduras</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :3560010</name>
      <address>
        <city>Ajmer</city>
        <zip>305001</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :3560002</name>
      <address>
        <city>Ambawadi</city>
        <zip>380015</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :3560007</name>
      <address>
        <city>Belagavi</city>
        <zip>590002</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :3560001</name>
      <address>
        <city>Jaipur</city>
        <zip>302039</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :3560005</name>
      <address>
        <city>Kanpur</city>
        <zip>208002</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :3560009</name>
      <address>
        <city>Nagpur</city>
        <zip>440001</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :3560011</name>
      <address>
        <city>Odisha</city>
        <zip>751003</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :3560004</name>
      <address>
        <city>Patna</city>
        <zip>801507</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :3560006</name>
      <address>
        <city>Tamilnadu</city>
        <zip>603203</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :3920005</name>
      <address>
        <city>Chiyoda-ku,</city>
        <state>Tokyo</state>
        <zip>101-0041</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :3920004</name>
      <address>
        <city>Haramachi,Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>162-0053</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :3920003</name>
      <address>
        <city>Kouenji minami,Suginami-ku</city>
        <state>Tokyo</state>
        <zip>166-0003</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :3920001</name>
      <address>
        <city>Kyobashi Chuo-ku</city>
        <state>Tokyo</state>
        <zip>104-0031</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :3920002</name>
      <address>
        <city>Ohta-ku</city>
        <state>Tokyo</state>
        <zip>143-0015</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :4040004</name>
      <address>
        <city>Kericho</city>
        <zip>00200</zip>
        <country>Kenya</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :4040002</name>
      <address>
        <city>Kisumu</city>
        <zip>40100</zip>
        <country>Kenya</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :5240002</name>
      <address>
        <city>Dhulikhel</city>
        <zip>45200</zip>
        <country>Nepal</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Colombia</country>
    <country>Ghana</country>
    <country>Honduras</country>
    <country>India</country>
    <country>Japan</country>
    <country>Kenya</country>
    <country>Nepal</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 26, 2021</study_first_submitted>
  <study_first_submitted_qc>May 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 27, 2021</study_first_posted>
  <last_update_submitted>October 1, 2021</last_update_submitted>
  <last_update_submitted_qc>October 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

